Why Skin Substitutes Have Become Part of the Diabetic Foot Conversation
Despite optimal offloading, debridement, infection control, and revascularization, a substantial proportion of diabetes-related foot ulcers fail to close within 12 weeks of standard care. Persistent non-healing carries real consequences: continued infection risk, hospitalization, and lower-extremity amputation. Cellular, acellular, and matrix-like products (CAMPs)—collectively known as skin substitutes or cellular and tissue-based products—have emerged as one of the most actively studied adjuncts in modern wound care, and recent international guidelines have moved them from the periphery of practice into the formal treatment algorithm for hard-to-heal diabetic foot ulcers.
What the Category Actually Includes
The umbrella term covers a heterogeneous set of biologic and bioengineered products, generally grouped by tissue source and cellular content:
- Bioengineered, cell-containing constructs such as bilayered living cellular skin substitutes (e.g., Apligraf) and human fibroblast-derived dermal substitutes (e.g., Dermagraft).
- Acellular dermal matrices derived from processed human cadaveric or animal dermis (e.g., GraftJacket, DermACell).
- Placental-derived products, including dehydrated human amnion-chorion membrane (dHACM), cryopreserved amniotic membranes, and umbilical-cord-derived grafts.
Their proposed mechanisms differ in detail but converge on a common principle: providing a biologically active scaffold of collagen, extracellular-matrix components, growth factors, and—in some products—viable cells that can modulate the chronic-wound microenvironment and shift it toward healing (Banerjee et al., Advances in Wound Care, 2024).
What the Randomized Evidence Shows
Bioengineered Living Skin Equivalents
Early pivotal trials of Apligraf and Dermagraft established the proof of concept that biologic adjuncts could outperform standard care in neuropathic diabetic foot ulcers. A systematic review of eight randomized controlled trials in 1,173 patients reported improved time-to-closure and higher complete-healing rates with bioengineered skin substitutes—including Apligraf, Dermagraft, GraftJacket, and OrCel—compared with standard care, along with lower infection rates in pooled analyses (Santema et al., Cochrane Database of Systematic Reviews, 2016).
Placental-Derived Membranes
Placental tissues have generated some of the most consistent recent randomized data. A prospective trial of dehydrated human amnion/chorion allograft reported wound closure in 70% of treated ulcers at six weeks versus 15% with standard care alone (Snyder et al., Wounds, 2016). A separate multicenter randomized trial of hypothermically stored amniotic membrane found significantly greater closure rates at 12 and 16 weeks compared with standard care, with a 75% increase in the probability of complete wound closure (Tettelbach et al., Journal of Comparative Effectiveness Research, 2019).
Pooled and Network Estimates
A 2024 meta-analysis of 29 randomized controlled trials including 2,255 patients found that adding a cellular or acellular matrix product to standard care nearly tripled the odds of complete wound closure (odds ratio 2.9; 95% CI 2.3–3.8) compared with standard care alone (Banerjee et al., Advances in Wound Care, 2024). A Bayesian hierarchical meta-analysis of 35 randomized trials cited in Medicare’s 2024 Local Coverage Determinations reached a similar conclusion, with a pooled posterior risk ratio of 2.0 (95% credible interval 1.69–2.38) for healing across CAMP categories (International Journal of Tissue Repair, 2024).
How International Guidelines Position These Therapies
The 2023 update of the International Working Group on the Diabetic Foot (IWGDF) guideline on wound-healing interventions reviewed the cumulative trial evidence and issued conditional supportive recommendations for both placental-derived products and other tissue-based therapies in diabetes-related foot ulcers (Chen et al., Diabetes/Metabolism Research and Reviews, 2024). The recommendation language is deliberate: these products are positioned as adjuncts to best standard of care—not replacements for offloading, debridement, infection management, and vascular optimization—and they are recommended for wounds that have failed to progress on standard care alone, in settings where the resources to support their use are available.
Practical Considerations and Limitations
Several caveats temper the enthusiasm reflected in pooled estimates. Many individual randomized trials are small and short, often follow patients for only 12–16 weeks, and may exclude the most complex ulcers—those with severe ischemia, deep infection, or exposed bone—limiting generalizability. Heterogeneity in product composition, application protocols (single versus weekly applications), and outcome definitions makes direct comparisons between products difficult. The 2024 systematic reviews highlight that recurrence rates after initial closure remain an under-reported endpoint, and head-to-head comparative effectiveness trials between major product families are still relatively scarce.
Clinical Takeaways
For ulcers that fail to demonstrate meaningful reduction in size—commonly defined as roughly 50% area reduction by week four—despite well-executed standard care, cellular and tissue-based products represent an evidence-supported adjunctive option endorsed by current international guidelines. The data are strongest for placental-derived membranes and for bioengineered skin equivalents in neuropathic ulcers, with consistent signals of higher closure rates and faster time-to-healing compared with standard care alone. They should be selected within a structured wound-care pathway that has already optimized offloading, perfusion, infection control, and debridement, and applied in patients whose wounds have plateaued under that pathway.
References
- Chen P, Vilorio NC, Dhatariya K, et al. Guidelines on interventions to enhance healing of foot ulcers in people with diabetes (IWGDF 2023 update). Diabetes/Metabolism Research and Reviews. 2024;40(3):e3644.
- Banerjee J, Lasiter A, Nherera L. Systematic Review of Cellular, Acellular, and Matrix-like Products and Indirect Treatment Comparison Between Cellular/Acellular and Amniotic/Nonamniotic Grafts in the Management of Diabetic Foot Ulcers. Advances in Wound Care. 2024.
- Santema TB, Poyck PPC, Ubbink DT. Skin grafting and tissue replacement for treating foot ulcers in people with diabetes. Cochrane Database of Systematic Reviews. 2016;(2):CD011255.
- Snyder RJ, Shimozaki K, Tallis A, et al. A Prospective, Randomized, Multicenter, Controlled Evaluation of the Use of Dehydrated Amniotic Membrane Allograft Compared to Standard of Care for the Closure of Chronic Diabetic Foot Ulcer. Wounds. 2016;28(3):70–77.
- Tettelbach W, Cazzell S, Reyzelman AM, et al. A confirmatory study on the efficacy of dehydrated human amnion/chorion membrane in the management of diabetic foot ulcers: A prospective, multicentre, randomised, controlled study of 110 patients. International Wound Journal. 2019;16(1):19–29.
- Bayesian hierarchical meta-analysis of CAMPS versus standard of care for diabetic foot ulcers: systematic review of evidence from Medicare’s 2024 Local Coverage Determinations. International Journal of Tissue Repair. 2024.
Comments
